Loading...
Market
What will be the primary use case for the PCANS nasal spray in the first year of release by December 31, 2025?
2
Resolution / Starting Odds
COVID-19 prevention • 25%
Influenza prevention • 25%
Bacterial infection prevention • 25%
General respiratory health • 25%
Market reports and public health guidelines
Story
New Drug-Free Nasal Spray Shows Nearly 100% Protection Against COVID-19, Influenza, and Bacteria
Sep 25, 2024, 06:06 PM
Researchers at Brigham and Women's Hospital, led by N Joshi and Jeff Karp, have developed an innovative drug-free nasal spray that shows promise in warding off respiratory infections. Preclinical studies indicate that the spray, known as Pathogen Capture and Neutralizing Spray (PCANS), offers nearly 100% protection against COVID-19, influenza, and pneumonia-causing bacteria. The spray works by blocking and neutralizing viruses and bacteria, potentially serving as an additional public health tool when masks and vaccines are insufficient. The development has been published in Advanced Materials and has received recognition from the Stepping Strong COVID Award.
View original story
Similar markets
Less than 1 million units • 25%
1 to 2 million units • 25%
2 to 3 million units • 25%
More than 3 million units • 25%
Yes • 50%
No • 50%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Personal Health Monitoring • 25%
Clinical Diagnostics • 25%
Occupational Health • 25%
Other • 25%
Yes • 50%
No • 50%
Pharmacies • 25%
Online retailers • 25%
Healthcare providers • 25%
Other • 25%
Yes • 50%
No • 50%
Pharmacies • 25%
Online retailers • 25%
Healthcare providers • 25%
Other • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%